BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://www.pharmajournalist.com X-WR-CALDESC:Events for Pharma Journalist REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Asia/Kolkata BEGIN:STANDARD TZOFFSETFROM:+0530 TZOFFSETTO:+0530 TZNAME:IST DTSTART:20200101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;VALUE=DATE:20210525 DTEND;VALUE=DATE:20210528 DTSTAMP:20260515T181415 CREATED:20201210T121300Z LAST-MODIFIED:20201210T121300Z UID:28242-1621900800-1622159999@www.pharmajournalist.com SUMMARY:Ligase Targeting Drug Development – Digital Summit DESCRIPTION:As the therapeutic value of manipulating previously hard-to-drug ubiquitin ligases becomes more and more evident in addressing numerous diseases with unmet clinical needs\, the inaugural Ligase Targeting Drug Development Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the day. \n \nBuilt with large pharma and biotech insight\, the Ligase Targeting Drug Development Summit is fully dedicated to enabling novel ligase discovery and characterization\, achieving cell and tissue specificity and expanding chemical biology tools to therapeutically leverage ubiquitin ligases for effective protein modulation or degradation strategies. \nAs leading pharma companies join forces to bridge the gap between the functional knowledge and true translational value of ubiquitin ligases and their associated ligands\, join us to advance your understanding\, differentiate your pipelines and tap into the uncapped therapeutic potentials of this emerging field. \nTo know more about Ligase Targeting Drug Development – Digital Summit please click here. URL:https://www.pharmajournalist.com/event/ligase-targeting-drug-development-digital-summit/ LOCATION:Digital Event ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20210525 DTEND;VALUE=DATE:20210528 DTSTAMP:20260515T181415 CREATED:20210118T161111Z LAST-MODIFIED:20210118T161111Z UID:28556-1621900800-1622159999@www.pharmajournalist.com SUMMARY:Gene Therapy for Muscular Disorders DESCRIPTION:With clinical holds lifting there has been more investment and clinical progress in the gene therapy for muscular disorders space than ever before\, yet the consequences of toxicity are not a distant memory. Despite the successes\, there are still withstanding challenges for gene therapy developers targeting the muscle when it comes to optimizing delivery and navigating toxicity to develop truly safe and transformative therapeutics for muscular disorders patients. \n \nThe first industry-dedicated Gene Therapy for Muscular Disorders Summit will focus on overcoming the translational and clinical challenges of developing genetic therapies targeting muscular disorders\, including Duchenne Muscular Dystrophy (DMD)\, Limb-Girdle Muscular Dystrophy (LGMD)\, Pompe Disease and X-Linked Myotubular Myopathy. \nWith a focus on AAV and gene editing technologies and insights from Pfizer\, Solid Biosciences\, Audentes and Vertex\, this niche 3-day agenda has been specifically designed to help industry experts to: \n\nOptimize your promoter choice and navigate IP challenges for more efficient delivery to muscular targets\nDiscover the next generation capsids being developed for improved muscle selectivity and reduced immunogenic responses\nUnderstand the biology of different immunogenic responses and hear feedback from trialled strategies to ensure optimal patient safety\nHear the latest research in muscular disorder biomarkers\nDefine clinically meaningful muscular endpoints to successfully and objectively measure muscular disease improvement\nTackle regulatory challenges to demonstrate gene therapy durability\nOvercome clinical challenges to manage patient heterogeneity for patient centric and meaningful trials\n\nJoin your peers to share\, learn and discuss at the first industry-focused Gene Therapy for Muscular Disorders. Overcome your immunogenicity challenges and mitigate toxicity with high doses targeting the muscle to successfully demonstrate durability with your gene therapy product. \nTo know more about Gene Therapy for Muscular Disorders please click here. URL:https://www.pharmajournalist.com/event/gene-therapy-for-muscular-disorders/ LOCATION:Virtual Event ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20210525 DTEND;VALUE=DATE:20210528 DTSTAMP:20260515T181415 CREATED:20210208T082747Z LAST-MODIFIED:20210208T090154Z UID:28850-1621900800-1622159999@www.pharmajournalist.com SUMMARY:3rd Microbiome Movement – Maternal & Infant Health Summit 2021 DESCRIPTION:Harness the Maternal-Infant Microbiome\, Establish New Mechanisms of Action\, and Develop Breakthrough Health Products that Proactively Prevent Disease Risk \nReturning for another year\, this platform will unite industry and academics in the exploration of preventative and therapeutic treatment of the microbiome during pregnancy and early life. The discussion during this 3-day conference will cover key periods of pregnancy\, birth and infant development to encompass a range of areas where therapeutic\, nutritional targeting and research can be undertaken. \nTake this opportunity to join the event and you can:  \n\nGain a complete understanding of the current research and therapeutic opportunities as we walk through the infant journey from in utero development through to the first 1000 days\nUnderstand the value of the mother’s experience and health for foetal development with talks from Siobhain O’Mahony and Mary Claire Kimmel\nDiscover new therapeutic research into the vaginal microbiome\, such as PhagoMed and Columbia University \nBuild a broader understanding of the benefits of prevention with Evolve Biosystems highlighting cost-saving from early life treatments and the NIH’s push to advance this area of science\nHear from Siolta Therapeutics and ParetoBio in developing therapeutic treatments for allergies\n\nJoin us to further your understanding of how cutting-edge science is helping establish a causal relationship between the maternal-infant microbiome and long-term health effects\, and how this can be translated to demonstrate clinically validated solutions. \nTo know more about 3rd Microbiome Movement – Maternal & Infant Health Summit 2021 please click here. URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-maternal-infant-health-summit-2021/ LOCATION:Virtual/Online ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20210525 DTEND;VALUE=DATE:20210528 DTSTAMP:20260515T181415 CREATED:20210215T090719Z LAST-MODIFIED:20210215T090719Z UID:29000-1621900800-1622159999@www.pharmajournalist.com SUMMARY:STING & TLR-Targeting Therapies Summit DESCRIPTION:This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. \nThis meeting comes at a critical point for the cancer immunotherapy field\, as researchers look to increase patient response rates and the efficacy on checkpoint inhibitors in several solid tumor indications. Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. \n \nUse this key forum to hone your innate immune activation strategies and deliver safe and effective treatments through systematic and intra-tumoral administration which can stimulate the adaptive immune arm\, counteract solid tumor-induced immunosuppression and increase response to checkpoint inhibitors. \nView the event guide for the full agenda! \nInnate Immune Checkpoints & Activation Pre-Focus Day \nIn addition to two full conference days to STING/TLR-targeting\, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells\, macrophages and myeloid-derived suppressor cells. \nAn executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system. \nView the full event guide for more information. URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies-summit/ LOCATION:Digital Event ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20210525 DTEND;VALUE=DATE:20210528 DTSTAMP:20260515T181415 CREATED:20210312T064902Z LAST-MODIFIED:20210312T065621Z UID:29303-1621900800-1622159999@www.pharmajournalist.com SUMMARY:Gene Therapy Analytical Development Europe DESCRIPTION:In the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \n \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \n To know more about Gene Therapy Analytical Development Europe please click here. URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development-europe/ LOCATION:Virtual ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/8f5rxa END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20210525 DTEND;VALUE=DATE:20210528 DTSTAMP:20260515T181415 CREATED:20210318T083358Z LAST-MODIFIED:20210318T120953Z UID:29402-1621900800-1622159999@www.pharmajournalist.com SUMMARY:Inner Ear Disorders Therapeutics Summit – Digital Event DESCRIPTION:Hearing loss has a huge impact on the quality of life for millions of people\, and as the average age of the population increases\, the need for curative life-changing therapies targeting hearing loss and inner ear disorders has never been more important. \n \nThe Inner Ear Disorders Therapeutics Summit is gathering the world’s leading biopharmaceutical companies and KOLs at the only industry-focused summit dedicated to the translation and clinical development of novel gene therapy\, cell therapy and small molecule-based approaches to treat inner ear disorders\, with the aim to progress the industry towards the first clinically approved therapy. \nJoin industry and academic experts to discuss the best preclinical modelling approaches for translative proof of concept data\, identify the most appropriate biological endpoints and overcome the major challenges to develop safe\, effective\, and clinically viable inner ear disorder therapies to address the unmet medical need. \nTo know more about Inner Ear Disorders Therapeutics Summit please click here. URL:https://www.pharmajournalist.com/event/inner-ear-disorders-therapeutics-summit-digital-event/ LOCATION:Digital Event ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com END:VEVENT END:VCALENDAR